Seikagaku Corporation
Basic Information
- Stock Code
- 4548
- Industry
- Pharmaceuticals
- Category Detail
- Biotechnology & Pharmaceuticals
- Prefecture
- Tokyo
- Establishment Year
- June 1947
- Listing Year
- November 1989
- Official Website
- https://www.seikagaku.co.jp/
- TSE Information
- TSE Information
- Yahoo! Finance
- Yahoo! Finance
- Other Companies
- Kyoryo Information & Communications, Technomasema, Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, Santen Pharmaceutical, Daiichi Sankyo, Otsuka Holdings, Meiwa Seisakusho
Overview
Seikagaku Corporation is a research and development-oriented company in the pharmaceutical industry founded in 1947, specializing in carbohydrate chemistry and deploying the world's first joint function improvement agent as a technological innovation company.
Current Situation
Seikagaku Corporation recorded consolidated net sales of approximately 34.9 billion yen and operating profit of approximately 4.5 billion yen for the fiscal year ended March 2022, maintaining a stable financial base. In its mainstay medical pharmaceuticals field, it develops and offers products based on advanced carbohydrate chemistry technology, including 'Artz,' the world's first joint function improvement agent using hyaluronic acid, and consigns sales to Kaken Pharmaceutical and Santen Pharmaceutical. As a research and development-oriented company, it has strengths in the industrialization of glyco-pharmaceuticals and also manufactures pharmaceutical active pharmaceutical ingredients. In sustainability, it actively engages in sustainable raw material procurement and environmental impact reduction, positioning business foundation strengthening by 2030 as a medium- to long-term strategy. Recently, it has invested in the development of advanced glyco-pharmaceuticals and the construction of CMC research facilities to enhance research capabilities. It is responding to changes in medical demand after the COVID-19 pandemic while keeping domestic and international market expansion in view. Going forward, it plans to continue challenging new fields armed with technological superiority in glyco-pharmaceuticals.
Trivia
Interesting Facts
- Succeeded in the world's first industrialization of chondroitin sulfate in 1950
- Manufactured and sold the world's first joint improvement agent with hyaluronic acid as the main ingredient in 1987
- Rare history of major transformation from a fisheries company to a pharmaceutical manufacturer
- Pioneer Japanese company specializing in R&D of glyco-pharmaceuticals
- Operates a large-scale factory in Kurihama, Kanagawa Prefecture, for mass production of carbohydrate products
- Head office in Marunouchi, Tokyo, with multiple business sites in the Kanto region
- Capital of over 3.8 billion yen, maintaining a stable financial base as a mid-sized pharmaceutical company
- Strengthens network through consignment sales to major industry players like Kaken Pharmaceutical and Santen Pharmaceutical
- Industrialization technology for glyco-pharmaceuticals protected by patents and technical know-how
- High specialization in carbohydrate research, with numerous joint research projects with pharmaceutical companies
- Expanding R&D capabilities into medical reagents and diagnostic drugs
- Equipped with specialized facilities in CMC (pharmaceutical manufacturing management) at the research institute
- Approximately 530 employees on a non-consolidated basis, with many allocated to R&D
- Stable stock listed on the Tokyo Stock Exchange Prime Market
- Aggressively creating new glyco-pharmaceuticals with high future potential
Hidden Connections
- Strong industry network through product sales to other major pharmaceutical companies such as Kaken Pharmaceutical and Santen Pharmaceutical
- Transition from fisheries to glyco-pharmaceutical manufacturer contributed to formation of unique technologies
- Deep technological ties with the medical reagent industry through carbohydrate chemistry technology
- Has accumulated joint research and technical alliances with many companies in the pharmaceutical industry
- Advancing technology provision not only domestically but also to overseas pharmaceutical markets
- Collaborating with small and medium-sized biotech ventures to explore new applications for glyco-pharmaceuticals
- Patent portfolio on complex carbohydrate technology serves as a strong defensive barrier compared to competitors
- Focusing on talent development in carbohydrate research through cooperation with local universities and research institutions
Future Outlook
Growth Drivers
- Global growth in the glyco-pharmaceutical market
- Increasing demand for joint disease treatments due to aging society
- Expanding demand for pharmaceutical APIs and intermediates
- Manufacturing efficiency improvements through advanced technologies
- Acceleration of global expansion
- Planned launch of new glycan preparations
- Increasing R&D expenditures in the pharmaceutical industry
- Establishment of sustainable manufacturing processes
- Expansion of the medical reagent market
- Expansion and strengthening of consignment sales partners
- Sophistication of CMC-related services
- Enhanced competitiveness through innovation
Strategic Goals
- Doubling domestic and international sales of glyco-pharmaceuticals
- Establishment of sustainable manufacturing systems
- Launch of new joint treatment drugs and international expansion
- Digitalization and optimization of manufacturing processes
- Expansion of joint research with pharmaceutical companies
- Strengthening environmental and social considerations in raw material procurement
- Building expansion bases in the medical reagent and diagnostic drug market
- Talent development and creation of a comfortable work environment
- Increased investments toward new business creation
- Strengthening global intellectual property management systems
Business Segments
Pharmaceutical Manufacturing Consignment
- Overview
- Provides consignment manufacturing of high-quality glyco-pharmaceuticals and research and development support.
- Competitiveness
- High technological strength in glyco-pharmaceutical manufacturing
- Customers
-
- Pharmaceutical companies
- Pharmaceutical research institutions
- Biotech ventures
- Products
-
- Glyco-pharmaceutical Synthesis
- Intermediate Manufacturing
- CMC Research Support
Medical Devices and Diagnostic Drug Manufacturing
- Overview
- Development and manufacturing of diagnostic drugs and devices used in medical settings.
- Competitiveness
- High-precision carbohydrate analysis technology
- Customers
-
- Hospitals
- Diagnostic companies
- Research institutions
- Products
-
- Inspection Carbohydrate Reagents
- Diagnostic Kits
- Medical Device Components
Research and Development Services
- Overview
- Deploys specialized services to support research and development in the glycan field.
- Competitiveness
- High expertise in glycan research know-how
- Customers
-
- University labs
- Pharmaceutical company R&D divisions
- Biotech companies
- Products
-
- Carbohydrate Chemistry Research Support
- New Drug Candidate Evaluation
- Analysis Technology Services
Raw Material Supply
- Overview
- Stably supplies high-quality carbohydrate raw materials and intermediates.
- Competitiveness
- Stable production through industrialization technology
- Customers
-
- Pharmaceutical companies
- Medical device manufacturers
- Products
-
- Carbohydrate Raw Materials
- Intermediate Raw Materials
Competitive Advantage
Strengths
- Proprietary carbohydrate chemistry technology and industrialization technology
- Track record of manufacturing the world's first hyaluronic acid preparation
- R&D-oriented organizational structure
- Stable distribution network and consignment sales system
- Solid financial base
- Specialized high manufacturing technology
- Diverse lineup of medical pharmaceuticals
- Business sites rooted in the region
- Technological innovation through external collaborations
- Advanced intermediate manufacturing capabilities
Competitive Advantages
- Technological superiority in the niche field specializing in carbohydrates
- Distribution channel building power through consignment sales to Kaken Pharmaceutical, Santen Pharmaceutical, etc.
- High brand recognition in the joint function improvement agent market
- Stable supply system based on sustainable raw material procurement
- Holding global patents for glyco-pharmaceuticals
- Mass production technology for high-purity carbohydrate products
- Unique product development using complex carbohydrate technology
- Highly reliable R&D capabilities within the industry
- Technology platform applicable to multiple pharmaceutical fields
- Market understanding and customer base based on long business history
Threats
- Risk of regulatory strengthening and legal amendments in the pharmaceutical industry
- Product development speed of major competing pharmaceutical companies
- Intensifying price competition due to globalization
- Risk of fluctuations in raw material costs
- Possibility of market share changes due to new technologies
- Risk of revenue decline due to patent expiration
- Expansion of competitors in emerging markets
- Impact of exchange rate fluctuations on earnings
- Risk of changes in medical demand since the COVID-19 pandemic
- Intensifying competition for talent acquisition
Innovations
2024: Development of New Joint Improvement Agent Using Carbohydrate Derivatives
- Overview
- Promoting research and development of a new joint function improvement agent utilizing cutting-edge carbohydrate chemistry.
- Impact
- Expected future market expansion as clinical trials commence
2023: Introduction of Latest Equipment to CMC Laboratory
- Overview
- Renewed research facilities to enhance pharmaceutical manufacturing and quality management.
- Impact
- Improved product quality through standardization and efficiency of manufacturing processes
2022: Improvement of Hyaluronic Acid Preparation Production Process
- Overview
- Significant improvement in production efficiency of hyaluronic acid preparations using enzyme utilization technology.
- Impact
- Contributes to 10% reduction in production costs and supply stabilization
2021: Commercialization of Glycan Analysis Technology
- Overview
- Successfully productized glycan testing kits and began deployment domestically and internationally.
- Impact
- Diversification of revenue base through new market development
2020: Establishment of Sustainable Carbohydrate-Derived Raw Material Procurement System
- Overview
- Implemented traceability enhancement measures for raw material procurement to reduce environmental impact.
- Impact
- Enhanced ESG response and establishment of long-term stable supply base
Sustainability
- Pharmaceutical packaging using sustainable biodegradable materials
- Implementation of biodiversity conservation programs for raw material sources
- Promotion of transition to low-environmental-impact manufacturing processes
- Promotion of waste reduction and improved recycling rates
- Company-wide penetration of environmental awareness through employee education
- Participation in environmental conservation activities in collaboration with local communities
- Energy-saving equipment investments and CO2 reduction targets
- Ensuring stable supply and safety of pharmaceutical raw materials
- Strengthening environmental risk management in the supply chain
- Implementation of measures for sustainable water resource utilization